Bristol-Myers Squibb (BMY) Shares Pop as Ipilimumab Reaches Primary Endpoint

March 21, 2011 5:08 PM EDT
Bristol-Myers Squibb (NYSE: BMY) shares are popping after-hours today following an announcement that ipilimumab clinical trial met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma. Shares are up 4.9% post-market.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Insiders' Blog, Trader Talk